NCCM
ECYT

Nine Chapters Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Nine Chapters Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-23,500
Closed -$60K – 234
2017
Q1 		$60K Buy
+23,500
New +$54.4K 0.08% 214

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return

Nine Chapters Capital Management's ECYT Position: Q2 2017 in Review

Nine Chapters Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2017, closing a stake of 23,500 shares — an estimated $60K sold.

Nine Chapters Capital Management first reported a position in ECYT in Q1 2017 and held it in 1 quarter. The position peaked at $60K in Q1 2017. 75 funds tracked by Wall St. Rank hold ECYT as of Q2 2017.

  • Nine Chapters Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Nine Chapters Capital Management sold 23,500 Endocyte, Inc. Common Stock shares in Q2 2017, an estimated $60K.
  • Nine Chapters Capital Management first reported a position in Endocyte, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Nine Chapters Capital Management's Endocyte, Inc. Common Stock position peaked at $60K in Q1 2017.
  • 75 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2017.

Based on Nine Chapters Capital Management's 13F filing for Q2 2017, filed 31 Jul 2017.